Enthera Pharmaceuticals is a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way.
Enthera Pharmaceuticals develops first-in-class biologics for several underserved autoimmune conditions.
Enthera Pharmaceuticals was founded in 2016 by Prof. Paolo Fiorina and Dr. Francesca D’Addio. The company is headquartered in Milan, Lombardy, Italy.
Enthera's therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases.
Enthera's primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD). The company's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.
Enthera is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-establish organ function.
Enthera is backed by Sofinnova Partners, AbbVie Ventures, JDRF T1D Fund, Banor SIM, Arepo Fiduciaria, Indaco Venture Partners SGR and others. The company raised €28M in Series A round on Jul 28, 2020. This brings Enthera's total funding to €32M to date.